Abstracts tagged "osteoarthritis and pain"

Abstract Number: 734 • 2012 ACR/ARHP Annual Meeting
Chemokine (C-C Motif) Receptor 2 Signaling Mediates Persistent Pain in Experimental Osteoarthritis
Rachel E. Miller¹, Phuong Tran², Rosalina Das², Nayereh Ghoreishi-Haack², Richard J. Miller³ and Anne-Marie Malfait⁴, ¹Rheumatology/Biochemistry, Rush University Medical Center, Chicago, IL, ²Rheumatology, Rush University Medical Center, Chicago, IL, ³Molecular Biochemistry and Pharmacology, Northwestern University, Chicago, IL, ⁴Internal Medicine/Biochemistry, Rush University Medical Center, Chicago, IL
Background/Purpose: To investigate the role of MCP-1/CCR2 in the development of pain in osteoarthritis (OA) using a mouse model, destabilization of the medial meniscus (DMM).…
Abstract Number: 273 • 2012 ACR/ARHP Annual Meeting
The Prevalence of Periarticular Lesions On Magnetic Resonance Imaging and Its Relation to Knee Pain in the Community Residents in Korea
In Je Kim¹, Kyeong Min Son², DH Kim³, Yeong Wook Song⁴, Ali Guermazi⁵ and Hyun Ah Kim⁶, ¹Internal Medicine, Hallym University Kangdong Sacred Heart hospital, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Hallym university Chunchun sacred heart hospital, Chunchun, South Korea, ³Preventive Medicine, Chunchon, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea, ⁵Boston University, Boston, MA, ⁶Department of internal medicine, Hallym University Sacred Heart Hospital, Kyunggi, South Korea
Background/Purpose: The purpose of this study was to investigate the prevalence of periarticular lesions detected by magnetic resonance imaging (MRI) and its association with…
Abstract Number: 259 • 2012 ACR/ARHP Annual Meeting
Long-Term Tanezumab Treatment for Osteoarthritis: Efficacy and Safety Results
Alfonso E. Bello¹, Evan F. Ekman², David Radin³, Isabelle Davignon⁴, Michael D. Smith⁵, Mark T. Brown⁵, Christine R. West⁶ and Kenneth M. Verburg⁵, ¹Illinois Bone & Joint Institute, Glenview, IL, ²Southern Orthopaedic Sports Medicine, Columbia, SC, ³Stamford Therapeutics Consortium, Stamford, CT, ⁴Pfizer, Groton, CT, ⁵Pfizer, Inc., Groton, CT, ⁶Clinical Sciences, Pfizer, Williamston, MI
Background/Purpose: Nerve growth factor (NGF) levels are associated with increased pain perception and are elevated in joints of arthritis patients. Tanezumab, a humanized monoclonal antibody,…
Abstract Number: 234 • 2012 ACR/ARHP Annual Meeting
Central Sensitization Is Associated with Spontaneous Pain in Knee Osteoarthritis
Anisha B. Dua¹, Tuhina Neogi², Rachel A. Mikolaitis³, Joel A. Block³ and Najia Shakoor⁴, ¹Rheumatology, West Penn Allegheny Health System, Pittsburgh, PA, ²Boston University School of Medicine, Boston, MA, ³Section of Rheumatology, Rush University Medical Center, Chicago, IL, ⁴Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Osteoarthritis (OA) is a chronic, prevalent disease that is a major cause of pain and disability. Pain is the primary symptom of OA, however…
Abstract Number: 235 • 2012 ACR/ARHP Annual Meeting
Peripheral and Central Sensitization in Patients with Different Degree of Knee Osteoarthritis
Lars Arendt-Nielsen¹, Thomas Navndrup Eskehave², Morten Asser Karsdal³, Anne C. Bay-Jensen⁴, Hans Christian Hoeck² and Ole Simonsen⁵, ¹Department of Health Science and Technology, Faculty of Medicine, Aalborg University, Center for Sensory-Motor Interaction, Aalborg, Denmark, ²Center for Clinical and Basic Research and C4Pain, Aalborg, Denmark, ³Nordic Bioscience A/S, Herlev, Denmark, ⁴Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ⁵Frederikshavn Hospital, Frederikshavn, Denmark
Background/Purpose: Though pain is the cardinal symptom of osteoarthritis (OA) the underlying causes are not fully understood. However, peripheral and central sensitization has been suggested…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.